




MEDYY I

Editing File



Metabolic Bone Disorders

Al

A2

Dr. Hisham Alsanawi


Color Index:



Dr. Abdullah Addar



Objectives



To be able to specify the symptoms and signs.

Outline the assessment and appropriate investigation.

Propose a limited differential diagnosis.

Outline the principles of management of a patient with:

- Osteoporosis.
- Osteomalacia & Rickets.

Although there was 2 different doctors, the questions was from Dr. Hisham's slides, **BUT** this file will include both slides "mixed".







Outline

- Basic science "bone metabolism": - Metabolic pathways.
- Clinical features & Medications.
- Specific disorders: Rickets/Osteomalacia. Renal osteodystrophy. Hypophosphatasia.
 - Osteogenesis imperfecta. Osteoporosis.

Introduction

- Orthopedic surgeons have to deal with all types of bone (healthy or diseased), and that's why they have to know about bone metabolism, metabolic bone disorders needs a long term observation that's why it needs a specialized person.
- Bone functions:
 - Protect vital organs & structures.
 - Mechanical support for muscles & tendons¹ and act as lever arm for muscles.
 - Storage and regulation of calcium.
 - Hematopoiesis (bone marrow).
- There is a continuous activity in bone (bone resorption and bone formation as well as remodeling) not a concrete during all stages of life, that means bone is not only for protection and support but its contents play an important part in blood homeostasis, and many factors are involved in this process².
- Bone is a living tissue formed by bone matrix which consists of 40% organic (connective tissue) mainly 'collagen type 1'³ (responsible for tensile strength⁴) and 60% minerals, mainly calcium hydroxyapatite, phosphorus, and traces of other minerals like zinc (provides compressive strength), so (collagen → tension | minerals (Ca²⁺) → compression)⁵.
- Bone Mass: Peak at 16-25 years, decreases by 0.3-0.5%/year after skeletal maturity, 2-3% decline/year in untreated post-menopausal women = osteoporosis, Improve/maintain bone mass by resistance medications, bone may become weak in certain conditions.
 - All bones aren't straight, normally they're curved.
- Bone cells:
 - Osteoblasts "bone forming cells", its function:
 - Regulate osteoclasts (RANKL + OPG).
 - Produce non-mineralized bone matrix "collagen type $1'' \rightarrow$ calcium + phosphate = Hydrox
 - Osteoclasts "bone resorbing cells" "bone macrophage".
 - Osteocytes":
 - 90-95% of all cells in bone.
 - Originate from osteoblasts.
 - Function to maintain bone and cellular matrix.
- Constant interplay between bone formation (Osteoblasts) and bone breakdown (Osteoclasts) → Bone remodeling, why remodel? Repair fatigue stresses from repeated micro-trauma.
 - Signaling pathways "RANK-RANKL-OPG pathway":
 - Bone formation:
 - Stimulate osteoblasts + inhibit osteoclasts.
 - Bone resorption:
 - Activation of osteoclasts.
 - Osteoblasts produce:
 - ${\scriptstyle \bullet}$ RANKL ${\rightarrow}$ Bind RANK ${\rightarrow}$ Stimulates osteoclasts ${\rightarrow}$ Bone resorption.

1- Tendons can't work with Determined to be a complete sign of the tender of tender o

2- While osteoblasts are forming new bones, osteoclasts are removing the dead or aged ones, this process accelerates with aging and when estrogen levels drop (e.g. menopause), the rate of formation decrease and the rate of loss increase (3% of bone mass will be lost yearly), the opposite happens in the childhood where bone formation is higher than resorption, any imbalance in this process will lead to disease.


3- There are other types but the majority of it in the bone are type 1.

4- Tensile strength is the measurement of the force required to pull something.

5- Minerals protect the bone from compressive forces (Push), while collagen protects the bone form tensile forces (Pull).



Bone Metabolism Factors 🎙



Systemic

- PTH:
 - Bone resorption.
- Vitamin D Calctriol 1-25 Hydroxyvitamin D:
 Increases bone mineralization.
- Calcitonin:
 - Limits bone resorption "inhibits osteoclasts".
- Sex hormones (Estrogen/Androgens):
 Increase BMD "bone mineral density".
- Growth hormone:
 Positive effect on bone formation.
- Thyroid Hormone:
 - Bone resorption.
- Corticosteroids:

- Cause bone loss by decreasing bone formation "inhibit collagen synthesis and activate cell death for osteoblasts".

Local

- Pro-resorptive cytokines:
 - IL-1, IL-6, GM-CSF..
 - Stimulate osteoclasts \rightarrow Bone resorption.
- Anti-resorptive cytokines:
 - IL-4, Interferon-B, Prostaglandin-E2.

- Inhibit osteoclasts differentiation \rightarrow Bone formation.

- NSAIDs inhibit bone healing in rats.
- TGF-B:
 - Inhibits RANKL → Bone formation.
- BMP "bone morphogenetic proteins":
 - Promoted osteoblast differentiation →
 Bone formation.
 - Given intraoperatively to promote bone formation.


1- Sedentary lifestyle can lead to osteoporosis after menopause.

2- Patients with intestinal problems (such as celiac disease) have poor calcium absorption.



Mechanical Forces

- Wolff's Law:
 - Bone remodels in response to mechanical stress.
 - Osteocytes detect mechanical load \rightarrow Bone formation/hypertrophy.
 - Clinically: Weight bearing + resistance training \rightarrow Increase BMD.
- Heuter-Volkmann Law:
 - Mechanical forces influence longitudinal growth.
 - Compression \rightarrow Inhibits longitudinal growth.
 - Distraction \rightarrow Accelerates longitudinal growth.
 - Clinically: Guided-Growth.




Bone Strength

- Affected by mechanical stress which means exercise and weight bearing (strengthening the bone) "Wolff's law".
- One of the most important factors which affect bone strength is the exercise, it helps in overcome osteoporitic problems, so any metabolic disease management must include special workout exercises with special equipments.
- Gets reduced with menopause and advancing age, and bed ridden patients.
- Reduced bone density on X-rays is called Osteopenia.
- Osteopenia is also a term used to describe a degree of reduced bone density, which if advanced becomes
 Osteoporosis (can be diagnosed only by DEXA).


Bone Density

- Bone density is diagnosed at current time by a test done at radiology department called: DEXA scan (Dual Energy X-ray Absorptiometry)¹, which is measured radiation absorption (more absorption → more density), they do it in three areas (vertebrae, wrist "distal of radius", and neck of femur) these bones get affected first and might get fractured easily (we need to protect them).
- However, increased bone density does not always mean increased bone strength, as sometimes in Brittle bone disease "osteogenesis imperfecta" (which is a dense bone) is not a strong bone but fragile bone which may break easily.
- The measurement of bone density will be expressed as a T score (see image).



1- It's very important to learn how to read the graph, you may be asked to do so.

2- If you suspect osteoporosis in the exam, you should choose the -2.5 or less, NEVER 2.5, FOCUS ON THE MINUS -



- Phosphorus: 0.9–1.3 mmol/l
 - → Both absorbed by intestine and secreted by kidney in urine.
- Alkaline phosphatase: 30-180 units/l (normal in osteoporosis, unless if there's complication like a fracture)
 - → Is elevated in bone increased activity like during growth or in metabolic bone disease or destruction, use it as a clue, it's not specific so can't tell you the diagnosis (indicator of bone metabolism).
- Vitamin D: 70-150 nmol/l (promotes Ca²⁺ absorption from kidney and intestines).



Not used in treatment due to its side effects.

- Secreted by **C cells** of thyroid gland.
- Its secretion is regulated by serum calcium.
- Its action is to cause inhibition of bone resorption and increasing calcium excretion by this it causes lowering
 of serum calcium.
 - → Inhibit reabsorption from kidney & intestine and trying to bring it back to the bone, used to be given as supplement but not anymore because of its side effects.



- Production levels are related to serum calcium levels, PTH secretion is increased when serum calcium is low (↓Ca²⁺→↑PTH).
- Action of PTH:
 - 1. Increases calcium levels in the blood by increasing its release from bone (osteoclastic activity).
 - 2. Increases intestinal absorption by activating vitamin D.
 - 3. Increases reabsorption from the kidney and increases the excretion of phosphorus.
- If the parathyroid hormone is high due to a body demand, that's mean calcium is low we need to increase it, how? From the bone (readily available) so basically you will sacrifice the bone for the seek of heart, brain & vital organs. So, it works as a storage for calcium.

	Hyperparathyroidism	
Primary	Secondary ¹	Tertiary ^{2,3}
Adenoma of the gland.	Low Ca ²⁺ (e.g. renal failure).	Prolonged or sustained stimulation = hyperactive nodule or hyperplasia. "when secondary hyperplasia leads to autonomous overactivity"

1- Partial resistance to PTH action leads to parathyroid gland hyperplasia and increased PTH secretion, often in patients with renal failure and osteomalacia (due to low or low normal serum calcium levels).

2- Irreversible clonal outgrowth of parathyroid glands, usually in long-standing inadequately treated chronic renal failure on dialysis.

3- It happened after long standing hyperparathyroidism, you treated the cause like adenoma, but the PTH hormone continues to be secreted.

<u>Metabolic Bone Disease</u>



Introduction

- Pathology in shape, strength, and structure of bone, resulting from altered bone homeostasis, examples: - Rickets. - Hypophosphatasia. - Osteogenesis Imperfecta. - Fibrous Dysplasia.
 - Osteomalacia. Osteoporosis. Hyper-PTH.
- General clinical features:
 - Electrolyte disturbances. Fractures (pathological/low-energy).
 - Bone deformity. Abnormal gait. Short stature

Osteoporosis + Osteopenia

- Decreased bone mass:
 - Decreased total amount of bone/unit volume \rightarrow Reduced density (but each unit volume is normal).
 - Normal mineralization unlike osteomalacia (the unit volume is reduced).
- Is it important?
 - 200 million people affected yearly, mainly post-menopause and age-related.
 - 1.5 million osteoporotic fractures/year (700k vertebra, 300 hip, 200k wrist).
- Diagnosis:

- Postmenopausal women/men with a T-score of ≤ -2.5 SD bone mineral density (BMD) measured through dual-energy X-ray absorptiometry (DEXA) at minimum of two sites: femoral neck, lumbar spine, or distal radius (in case scanning cannot be done at the hip or spine) is considered to have osteoporosis (this is a diagnostic and not a therapeutic threshold).


- Presence of low-trauma (fragility) fracture (hip, spine, distal radius, proximal humerus) irrespective of BMD readings.


Osteopenia (T-score – 1.0 to – 2.5) on DEXA scan and high FRAX score based on country-specific threshold.
 Osteopenia or low bone mass is not a separate disease entity and should be used for epidemiologic purpose only.

• FRAX (Fracture Risk Assessment Tool):


- For fracture probability, Saudi Arabian FRAX model should be used for citizens, use other country-specific FRAX models for expatriates based on country of birth.

- FRAX can be calculated without DEXA at baseline:
 - High-risk patients (see below for risk stratification) should be treated.
 - Intermediate risk, BMD should be measured using DEXA and FRAX recalculated with DEXA readings added.
- Peripheral scanning using ultrasound may be used for screening but not for diagnosing osteoporosis.






Healthy bone Osteoporosis



The incidence of fractures of the vertebrae, hip and wrist rises progressively after the menopause.

Osteoporosis Types



Primary Osteoporosis				
Туре	Postmenopausal	Senile		
Description	 Due to rapid decline in estrogen level. This results in increased osteoclastic activity. Normal bone loss usually 0.3% per year (varies between people). Post-menopausal bone loss 3% per year (10x folds than normal). 	 Usually by 7th to 8th decades there is steady loss of at least 0.5% per year. It is part of physiological manifestation of aging. 		
Risk Factors	 Race (Caucasian "white ladies"). Hereditary. Body build (thin people). Early menopause. Smoking, alcohol intake, drug abuse. Low calcium intake. Inactivity "chronic lack of exercise". 	 Male menopause (decreased testosterone). Dietary: Less calcium and vitamin D and protein. Muscle weakness. Reduced activity (exercise is the best way to delay osteoporosis in men). 		
 Osteoporosis is a silent disease (asymptomatic until complications happen). Osteoporosis is serious due to possible complications, mainly fractures. Most common site (vertebra), 2nd most common (distal radius), most serious (hip). The best way to treat osteoporosis is to prevent it in the first place. Osteoporosis does not cause pain usually "painless unless it causes fractures". Osteoporosis leads to loss of height due to collapsed vertebrae "shorter back". Osteoporosis is not osteoarthritis, but the two conditions may co-exist. 				

Secondary Osteoporosis

It happens most of the time in young patients e.g. 45 years old, causes include:

- Drug induced: Steroids (especially in young people), alcohol, smoking, phenytoin, heparin, immunosuppressives.
- Hyperparathyroidism, hyperthyroidism, Cushing's syndrome, gonadal disorders, malabsorption, malnutrition, osteogenesis imperfecta.
- **Chronic diseases:** RA, renal failure, tuberculosis, ankylosing spondylitis, COPD.
- Malignancy: Multiple myeloma, leukemia, metastasis.

Kyphosis and Height Loss "Dowager's hump"	 With osteoporosis the anterior part of the vertebra narrows which leads to Kypho boss of h coss of h
Osteoporotic Fractures 'Fragility Fractures"	 They are pathological fractures. Most common is vertebral osteoporotic compression fracture (OVC fractures), they present with back pain. Vertebral micro-fractures occur unnoticed (dull ache). Most serious is hip fractures (high mortality rate). Also common is wrist fractures (Colles' fracture "distal radius"). We must observe the hip & the vertebrae.
Disuse Osteoporosis	 State of bone loss due to local skeletal unloading or systemic immobilization. Occurs locally adjacent to immobilised bone or joint. May be generalised in in bed-ridden patients or ICU patients. Awareness of and attempts for prevention are helpful (by moving the limb).

General Management

Nutrition Counceling	1	Improve calcium intake
Nutrition Counseling	2	Increasing vitamin D intake
Dhucical Activity Counceling	3	Weight-bearing and muscle strengthening exercise
Physical Activity Counseling	4	Fall prevention education
	5	Smoke cessation
Lifestyle Counseling	6	Limiting excessive alcohol intake
Pharmacotherapy	7	Pharmacotherapy
Testing	8	Testing bone mineral density: DXA (Dual Energy X-Ray Absorptiometry)
Communication	9	Physician referral letter to repot the patient's fragility fracture, risk factors, and recommendations for treatment
Communication	10	Patient education letter to explain bone health risk factors and recommendations for treatment



Indication: Based on DEXA scan "-2.5 or less" & FRAX score.

	Management
Drug Therapy	 Estrogen has a definite therapeutic effect and was used extensively as HRT but cannot be recommended now (not used anymore) due to serious possible side effects (such as tumors and CV risks). Adequate intake of calcium and vitamin D is mandatory (prior to and with treatment). Drugs which inhibit osteoclast activities: E.g. Oral Bisphosphonates as first line of treatment for most patients like sodium alendronate (FOSAMAX, BONVIVA). Drugs that enhance osteoblast activities: Bone stimulating agents like strontium (PROTELOS), teriparatide (FORTEO). The problem in this type of medication is the risk of malignancy. Denosumab, zoledronic acid, teriparatide, and romosozumab are other alternative 1st line therapies for specific groups of patients and when bisphosphonates are not feasible, contraindicated or failed. Every treatment option has recommended duration for use, after which the patient should be assessed for the need to continue treatment or go through drug holiday, a drug holiday is not feasible with denosumab because of the increased risk of vertebral fractures after stopping treatment, so another agent should be prescribed if denosumab is discontinued.
Exercise	 Resistive exercises. Weight bearing exercises e.g. Walking. Exercise should be intelligent to avoid injury which may lead to fracture.
Management of Fractures	 Use of load shearing (brace) implants in fracture internal fixation instead of plating. Plates = load bearing "all pressure on it" Screws "IM nail" (preferred)= load sharing "some pressure on it and some on bone". Pain relief. Prevention of further fractures and instability. Vertebroplasty and kyphoplasty.
Vertebroplasty Previewers vertebropter Vertebropter	 It's the injection of bone cement into the collapsed vertebra through pedicles. The injection is done under X-ray control (image intensifier) by experienced orthope or interventional radiologist. It results in immediate pain relief. It helps to prevent further OVF "osteoporotic vertebral fracture". Possible complication is leakage of cement into spinal canal (nerve injury) or venous blood (cement PE), burns around the tissue.
<section-header><complex-block><image/></complex-block></section-header>	 Used more than vertebroplasty. It's the injection of bone cement into the collapsed vertebra AFTER inflating a balloon "ballon then cement" in it to correct collapse and make a void (empty space) into which cement is injected. It is possible that some correction of kyphosis is achieved. It is safer because cement is injected into a safe void (low leakage risk).



Prevention of Osteoporosis

- Prevention of osteoporosis should start from **childhood** (especially girls).
- Healthy diet, adequate sunshine, regular **exercise**, avoidance of smoking or alcohol, caution in steroid use.
- At some time in the past there was a recommendation of HRT (Hormone Replacement Therapy) for postmenopausal women and men, **but now this is discontinued**.

Comparison

HECENTRY	Osteomalacia	Osteoporosis
Onset	Any age	Postmenopausal, old age
illness	ill	Not ill (unless complications)
Symptoms	Generalized chronic ache Asymptomatic until fractures	
Muscles	Weak Normal	
X-ray	Looser zones Nil (late X-ray changes)	
ALP	Increased	Normal
PO ₄	Decreased Normal	

Comparison of Osteoporosis and Osteomalacia		steomalacia
	Osteonorosis	Osteomal

	•	Osteoporosis	Osteomalacia
Definition Mineralized Mineralized matrix Normal		Unmineralized matrix Vineralized matrix Bone mass decreased, mineralization normal	Unmineralized matrix Mineralized matrix Bone mass variable, mineralization decreased
Age at onset		Generally elderly, postmenopause	Any age
Etiology		Endocrine abnormality, age, idiopathic, inactivity, disuse, alcoholism, calcium deficiency	Vitamin D deficiency, abnor- mality of vitamin D pathway, hypophosphatemic syndromes, renal tubular acidosis, hypophosphatasia
Symptomatology		Pain referable to fracture site	Generalized bone pain
Signs		Tenderness at fracture site	Tenderness at fracture site and generalized tenderness
Radiographic features		Axial predominance	Often symmetric, pseudofractures, or completed fractures Appendicular predominance
Laboratory	Serum Ca++	Normal	Low or normal (high in hypophosphatasia)
findings	Serum P _i	Normal Ca ⁺⁺ x P _i >30	(nigh in hypophosphatasia) Low or normal $Ca^{++} \times P_i > 30$ if albumin normal (high in renal osteodystrophy)
All	kaline phosphatase	Normal	Elevated, except in hypophosphatasia
	Urinary Ca++	High or normal	Normal or low (high in hypophosphatasia)
	Bone biopsy	Tetracycline labels normal	Tetracycline labels abnormal

Osteoporosis

Reduced amount of bone

Osteo<u>M</u>alacia Normal amount of bone, but reduced Mineralization of normal osteoid



Hyperparathyroidism

- Excessive PTH secretion: Primary, secondary or tertiary.
- Leads to increased bone resorption, subperiosteal erosions, osteitis manifested by fibrous replacement of bone.
- Significant feature is hypercalcemia "renal stones, constipation".
- In severe cases: Osteitis fibrosa cystica and formation of brown tumors.

2

X-ray Changes	 Generalized decrease in bone density. Sub-periosteal bone resorption (scalloping of metacarpals and phalanges "hands mainly"). Brown tumors (empty bone areas with bleeding caused by bone reuptake, not a true tumor). Chondrocalcinosis "calcification of the cartilage around joints" (wrist, knee, shoulder).
Management	 By management of the cause: Primary hyperparathyroidism due to neoplasm (adenoma or carcinoma) by excision. Secondary hyperparathyroidism by correcting the cause of hypocalcemia. Tertiary hyperparathyroidism by excision of hyperactive (autonomous) nodule. Extreme care should be applied after surgery to avoid hypocalcemia due to hungry bones syndrome "severe resistant hypocalcemia". One of the very important things you must pay attention to, it needs a lot of monitoring, the moment you correct hyperparathyroidism (1st 48 hours is critical), the bone might absorb a lot of calcium leading to severe hypocalcemia, that might lead to cardiac problems (cardiac arrest) or convulsions, if that happens it is very difficult to correct the hypocalcemia.



Early erosions



Scalloped distal phalanges



Brown tumors



Chondrocalcinosis

TABLE 3 Lab Comparison				
Hyperparathyroidism	Calcium	PTH	Vitamin D	Phosphate
Primary	\uparrow	$\uparrow \!$	\uparrow	\downarrow
Secondary	$\psi \rightarrow$	\uparrow	\downarrow	↑ or ↓
Tertiary	\uparrow	$\uparrow\uparrow$	\downarrow	1
Key: \uparrow Elevated, \downarrow decreased, \rightarrow normal.				

Rickets & Osteomalacia




	Rickets	Osteomalacia	
	Different expressions of the same disea	ase, which is: Inadequate mineralization.	
Pathology	 Failure of mineralization of cartilage and osteoid tissue. Decreases longitudinal bone growth and weakness mechanical properties of tubular bone. Qualitative defect (osteoporosis is a quantitative defect). 		
Onset	 Prior to skeletal maturity (open growth plates) in children. After skeletal maturity (closure of growth plates) in adults. 		
Affected Site	• Areas of endochondral growth (e.g. proximal humerus and proximal femur). • All skeleton is incompletely calcified (slowly progressive).		
Biochemistry	 Hypocalcemia (always check Ca²⁺, PO₄, vitamin D and ALP levels). Hypocalciuria. High alkaline phosphatase. 		
Causes	 Calcium deficiency (diet, malabsorption). Hypophosphatemia (to deposit calcium you need phosphate). Defect in vitamin D metabolism: Nutritional "vegan", underexposure to sunlight, intestinal malabsorption "celiac disease", liver & kidney diseases. 		

3

Description	Metabolic bone disorder in adults.	
Clinical Features (The difference here is that the growth is stopped in Adults unlike children so no growth-related symptoms here)	 Bone pain mainly backache, muscle weakness, fatigue. Reduced bone density. Vertebral changes: Biconcave vertebrae, vertebral collapse (shortening), kyphosis, scoliosis. Stress fractures "late": Looser's zones in scapula, ribs, pelvis, proximal femur. 	
	Medical: • Both "vitamin D + calcium" + lifestyle modification + exercise + sun exposure.	
Management	Surgical:	
	 Fracture management. Correct deformity if needed "the residual deformities only (after treatment)". 	
Femoral head stress fracture "Looser's zone"		

Kyphosis "advanced stage"



Looser's zones in the pubic rami and left femoral neck

Rickets

Diagnosis	• Based on: Clinical features, radiographs (X-ray), labs, +/- genetics.
	 Depends on age of onset. Infants: Generalized muscle weakness. Lethargy, irritability. Hypotonia. Delayed closure of skull fontanelles. Craniotabes: Softening of skull bones.
Clinical Features (The growth plate got affected, many symptoms due to that)	 Child is restless, babies cry without obvious reason. Failure to thrive. Limb deformities, mostly "lower limbs": Bowing: Genu varum "early". Genu valgum "late". Bone pain, coxa vara, difficulty walking. Joint thickening "hypertrophy" of ankles, and especially around wrists and knees. Wrist is the most important X-ray to confirm the diagnosis.
	 Ligamentous laxity. Enlargement of costal cartilage: Rachitic rosary. Pigeon chest deformity "pectus carinatum", harrison's sulcus. In severe cases with very low calcium: Tetany or convulsions.
X-ray Changes	 Growth plate (physeal) widening & thickening. Metaphyseal cupping. Long bone deformities. Fraying of metaphysis (Indistinct borders). Decreased bone density. Looser's zones, pseudofracture on the compression side of bone. Rachitic rosary: Prominence of rib heads at the osteochondral junction. Genu varum/valgum. Codfish vertebrae. Cat back: Dorsal kyphosis.
	Medical:
Management	 Adequate vitamin D replacement. Sun exposure. Calcitriol (1-25 vitamin D). Phosphate replacement. Calcium. Burosomab. Check if there's no systemic illness "treat the cause".
	Surgical:
	 Case by case to correct residual deformities (post rachitic) by corrective osteotomy. Don't perform surgery immediately because the bone is still growing, after 18-24 months of treatment. Treat fractures.
Ch	ild with abdominal symptoms + rickets features \rightarrow Refer to pediatrician

33

Rickets Types

Vitamin D Resistant Rickets	 Most common heritable form (XLD, AR, AD). Inability of renal tubules to absorb phosphate. Also known as: Familial hypophosphatemic rickets.
Nutritional	 Dietary. Celiac disease or hepatic disease Rickets of prematurity: Premature infants in NICU. TPN, hepatobiliary disease, diuretic therapy, etc Drug-induced rickets "Anti-epileptics in children": Child + Seizure disorder on medication + frequent fractures.
Vitamin D Dependent	 Type 1: Inability to hydroxylate. Type 2: Receptor insensitivity.
Renal Osteodystrophy	 Definition: Biochemical + skeletal manifestation of CKD or ESRD. Pathophysiology: Damaged kidney → Inability to excrete PO₄ → Hyperphosphatemia. Orthopedic issues: SCFE "slipped capital femoral epiphysis, discussed in pediatric hip lecture". AVN "avascular necrosis". Bowing of long bones.
Hypophosphatasia	 Inherited disorder resulting in rickets-like features. Main pathology is decreased or lack of alkaline phosphatase (ALP).

Table 42-1 Biochemical Abnormalities in Rickets

			Biochemical Al	Biochemical Abnormality		
Type of Rickets	Calcium	Phosphate	Alkaline Phosphatase	РТН	25-(OH) vitamin D	1,25-(OH)₂ vitamin D
Nutritional	NI	NI↓	\uparrow	\uparrow	$\downarrow\downarrow$	\downarrow
Vitamin D–resistant (XLH, RTA, Fanconi, oncogenic)	NI	\downarrow	↑	NI	NI	NI
Vitamin D–dependent type I (inability to hydroxylate)	\downarrow	\downarrow	↑	Ŷ	$\uparrow \uparrow$	$\downarrow\downarrow$
Vitamin D-dependent type II (receptor insensitivity)	\downarrow	\downarrow	↑	Ŷ	NI↑↑	$\uparrow \uparrow \uparrow \uparrow$
Renal osteodystrophy	NI↓	1	↑	$\uparrow \uparrow$	NI	$\downarrow\downarrow$

S. Fr



Definition	 Genetic connective tissue disorder affecting the formation of type 1 collagen. COL1A1, COL1A2.
Pathology	 Type 1 collagen is reduced in quantity. Some have a quality issue with mutant collagen. Weaker bones.
Types	 Sillence classification: Type 1: Mild form. Type 2: Lethal form. Type 3: Severe deforming form. Type 4, 5, others: Variable features.
	Orthopedic:
Clinical Features	 Multiple fractures + increased bone fragility: Olecranon apophyseal avulsion fractures in children are pathognomonic for Ol. Might be 1st sign of disease, especially milder forms. Bowing. Short stature. Kyphoscoliosis. Basilar invagination. Ligamentous laxity. Radial head dislocation. Coxa vara.
	Non-Orthopedic:
	 Blue sclera. Dentinogenesis imperfecta. Hearing loss. Bleeding tendency. Triangular facies. Low set ears.
	 Hyper-metabolism (risk of malignant hyperthermia). Cardiovascular: Mitral prolapse, aortic regurgitation.
X-ray Changes	
X-ray Changes Management "Medical + Surgical	 Cardiovascular: Mitral prolapse, aortic regurgitation. Generalized osteopenia/demineralization of bone Frequent fractures: Multiple fractures at different stages of healing. More than 3 rib fractures in a child → Rule out osteogenesis imperfecta. Delayed skull ossification and Wormian bones:
Management	 Cardiovascular: Mitral prolapse, aortic regurgitation. Generalized osteopenia/demineralization of bone Frequent fractures: Multiple fractures at different stages of healing. More than 3 rib fractures in a child → Rule out osteogenesis imperfecta. Delayed skull ossification and Wormian bones: Wormian bone is extra skull bones occurring within a suture (skull joint).
Management "Medical + Surgical	 Cardiovascular: Mitral prolapse, aortic regurgitation. Generalized osteopenia/demineralization of bone Frequent fractures: Multiple fractures at different stages of healing. More than 3 rib fractures in a child → Rule out osteogenesis imperfecta. Delayed skull ossification and Wormian bones: Wormian bone is extra skull bones occurring within a suture (skull joint).

Long bone telescoping rodding as soon as the child starts pulling to stand.

Table 1. Impact of Medications on Bone Homeostasis

Medication	Mechanism of Action	Effects on Bone
Diphosphonates ¹⁹	Inhibit osteoclast differentiation and function and promote apoptosis	Inhibit resorption and improve BMD
Denosumab ¹⁹	Anti-RANKL antibody	Inhibit resorption and improve BMD
Parathyroid hormone (PTH; teriparatide) ^{16,29,30}	Promote osteoblast RANKL secretion	Stimulate resorption and may promote fracture healing
NSAIDs ³¹	Inhibition of COX-1 and COX-2 enzymes and decrease PGE_2	Impaired bone healing, clinical effect likely duration dependent
Methotrexate (MTX) ¹⁹	Inhibits osteoblast proliferation at high doses	Neutral at low doses used for rheumatologic disease; decreases bone formation at higher doses
Antiepileptics ¹⁹	Effect on the CYP-450 pathway adversely affects the vitamin D-PTH-calcitonin axis	May cause rickets and osteomalacia
Statins ¹⁹	Increase osteoblast BMP-2 release and decrease osteoclast differentiation	Improve BMD
Corticosteroids ³²	Initiate proapoptotic pathways in osteoblasts	Diminish osteogenesis

Surgical Treatment in Metabolic Bone Disease

Principles + Techniques			
Protect the Entire Bone Segment if Possible	• Use intramedullary implants, if possible, nails better than plates.		
Promote Weight Bearing ASAP	• Load-sharing implants (nails) better than load bearing (plates).		
Augment Fixation (Don't rely on poor biology)	 Use cement. Use bone substitutes. Purchase more bone. 		











Important Notes

Dr. Hisham Alsanawi's Notes:

Bone metabolism:

- **Calcium & Phosphorus** are important factors controlling metabolism.
- **Bone strength** is affected by **mechanical stress** = **Exercise** is important.
- **Osteoporosis** only diagnosed with **DEXA** "-2.5 or less".
- Production of **PTH** is related to serum **calcium** level.
- **Tertiary** hyperparathyroidism: **Prolonged** sustained stimulation.

Rickets & Osteomalacia:

- X-ray findings of Rickets: Growth plate widening and thickening Metaphyseal cupping Long bones deformity.
- First start with vitamin D & calcium replacement, don't do surgery for the deformities at first, after treatment only you can correct the residual deformities by corrective osteotomy.

Osteoporosis:

- Primary **senile** osteoporosis important risk factor is **reduced activity**.
- The best & first line treatment is bisphosphonates

Important to differentiate between osteomalacia and osteoporosis by the table in the team last slide, but generally **ALP & PO4 are normal in osteoporosis**.

Dr. Abdullah Addar's Notes:

- Patient present with S&S of rickets and have epilepsy -> Drug-induced rickets.
- Avulsion of olecranon apophyseal fracture is pathognomonic for Osteogenesis imperfecta in children.
- Osteogenesis imperfecta -> Surgery (to protect the entire segment) & medical (bisphosphonates).
- Patient presented with **hypocalcemia**, **abdominal pain** and S&S of **rickets**, what to do next? Investigate for **celiac disease**.



Olceranon apophyseal fracture



Long bone deformities



Growth plate widening



Metaphyseal cupping

Toronto Notes

Metabolic Bone Disease

• see 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis for details

Osteoporosis

Definition

- a condition characterized by decreased bone mass and microarchitectural deterioration with a consequent increase in bone fragility and susceptibility to fracture
- BMD is measured at hip and lumbar spine, BMD T-score ≤-2.5 is indicative of osteoporosis
- osteopenia (low bone mass): BMD with T-score between -1.0 and -2.5

ETIOLOGY AND PATHOPHYSIOLOGY

Secondary Osteoporosis

- gastrointestinal diseases
 - gastrectomy
 - malabsorption (e.g. celiac disease, IBD, bariatric surgery)
 - chronic liver disease
 - eating disorder
 - poor nutrition
- bone marrow disorders
 - multiple myeloma
 - lymphoma
 - leukemia
- endocrinopathies
 - Cushing's syndrome
 - hyperparathyroidism
 - hyperputation
 hyperphyroidism
 - premature menopause
 - DM
 - hypogonadism
- malignancy
 - secondary to chemotherapy
 - myeloma

Clinical Features

- commonly asymptomatic
- height loss due to collapsed vertebrae
- fractures: most commonly in hip, vertebrae, humerus, and wrist (see Figure 22, E49)
 - fragility fractures: fracture with fall from standing height or less (does not include fractures of fingers and toes)
 - Dowager's hump: collapse fracture of vertebral bodies in mid-dorsal region
 - x-ray: vertebral compression fractures (described as wedge fractures, require a minimum of 20% height loss), "codfishing" sign (weakening of subchondral plates and expansion of intervertebral discs)
- pain, especially backache, associated with fractures

Approach to Osteoporosis

- 1. assess risk factors for osteoporosis on Hx and physical
- 2. decide if patient requires BMD testing with dual-energy x-ray absorptiometry (DEXA): men and women ≥65 yr (or younger if presence of risk factors, see Table 32, E48)
- 3. initial investigations
 - all patients with osteoporosis: calcium corrected for albumin, CBC, creatinine, ALP, TSH
 also consider serum and urine protein electrophoresis if vertebral fractures, celiac workup, and
 - 24 h urinary Ca²⁺ excretion to rule out additional secondary causes
 - 25-OH-vitamin D level should only be measured after 3-4 mo of adequate supplementation and should not be repeated if an optimal level ≥75 nmol/L is achieved
 - lateral thoracic and lumbar x-ray if clinical evidence of vertebral fracture (or in individuals at moderate risk of fracture to help decide if they require medical therapy)
- 4. assess 10-yr fracture risk by combining BMD result and risk factors
 - 1). WHO Fracture Risk Assessment Tool (FRAX)
 - 2. Canadian Association of Radiologists and Osteoporosis Canada Risk Assessment Tool (CAROC)
- approach to management guided by 10-yr risk stratification into low, medium, and high-risk
 5. for all patients being assessed for osteoporosis, encourage appropriate lifestyle changes (see Table 33, E48)

- rheumatologic disorders
 - rheumatoid arthritis
 - SLE
 - ankylosing spondylitis
- drugs and chemotherapy
 - corticosteroid therapy
 - anti-epileptic drugs
 - chronic heparin therapy
 - androgen deprivation therapy
 - aromatase inhibitors
- renal disease
- immobilization
- COPD (due to disease, tobacco, and glucocorticoid use)



Corticosteroid Therapy is a Common Cause of Secondary Osteoporosis Individuals receiving ≥7.5 mg of prednisone daily for over 3 mo should be assessed for bone-sparing therapy Mechanism: increased resorption + decreased formation + increased urinary calcium loss + decreased intestinal calcium absorption + decreased sex steroid production



Calcium plus Vitamin D Supplementation and Risk of Fractures

Osteoporosis Int 2015;27:367-376 **Purpose:** To review trials of vitamin D and calcium therapy for reducing fracture risk in osteoporosis. **Study:** Systematic review searching 2011-2015, inclusive, identified 8 RCTs totaling 30970 participants. RCTs reviewed included healthy adults and ambulatory older adults with medical conditions (excluding cancer). Vitamin D and calcium combination therapy was compared to placebo.

Results: Analysis of RCT data revealed that calcium plus vitamin D supplementation produced a statistically significant reduction in risk of total fractures (0.85; CI:0.73-0.98) and in hip fractures (0.70; CI:0.56-0.87). Subgroup analysis was significant for community dwelling or institutionalized patients. **Conclusions:** Systematic analysis suggests that vitamin D and calcium therapy significantly decreases fracture risk. This study did not specifically look at individuals with osteoporosis. However, it still supports that vitamin D and calcium should continue to be used as preventive treatment for individuals at increased risk of fractures.



Vitamin D and Calcium for the Prevention of Fracture: A Systematic Review and Meta-analysis JAMA Netw Open 2019;2:e1917789

Purpose: To investigate if fracture risk is associated with supplementation with vitamin D alone or vitamin D in combination with calcium.

Study Selection: Observational studies with \geq 200 fracture cases and RCTs with \geq 500 participants that reported \geq 10 incident fractures.

Results: Vitamin D supplementation alone was not associated with a reduced risk of any fracture or hip fracture (RR, 114; 95% Cl, 0.98-1.32). However, combined supplementation with vitamin D (400-800 IU daily) and calcium (1000-1200 mg daily) was associated with a 6% reduction in fracture risk (RR, 0.94; 95% Cl, 0.89-0.99) and a 16% reduction of hip fracture risk (RR, 0.84; 95% Cl, 0.72-0.97). Conclusion: Vitamin D alone was not associated with reduced fracture risk but daily supplementation with a combination of vitamin D and calcium was.



Clinical Signs of Fractures or Osteoporosis

- Height loss >3 cm (Sn 92%)
- Weight <51 kg (Sp 97%)
- Kyphosis (Sp 92%)
- Tooth count <20 (Sp 92%)
- Grip strength
- Armspan-height difference >5 cm (Sp 76%)
- Wall-occiput distance >4 cm (Sp 92%)
 Rib-pelvis distance ≤2 finger breadth (Sn 88%)



Online Clinical Tools

CAROC www.osteoporosis.ca/multimedia/pdf/ CAROC.pdf FRAX www.shef.ac.uk/FRAX/tool.aspx



Toronto Notes



Table 31. Indications for BMD Testing

		0.046313300.0	
Older Adults (age ≥50 yr)	Younger Adults (age <50 yr)		
All women and men age ≥65 yr Menopausal women, and men 50-64 yr with clinical risk factors for fracture: Fragility fracture after age 40 Prolonged glucocorticoid use Other high-risk medication use (aromatase inhibitors, androgen deprivation therapy) Parental hip fracture Vertebral fracture or osteopenia identified on x-ray Current smoking High alcohol intake Low body weight (<60 kg) or major weight loss (>10% of weight at age 25 yr) Rheumatoid arthritis Other disorders strongly associated with osteoporosis: primary hyperparathyroidism, T1DM, osteogenesis imperfecta, uncontrolled hyperthyroidism, hypogonadism or premature menopause (<45 yr), Cushing's disease, chronic malnutrition or malabsorption, chronic liver disease, COPD, and chronic inflammatory conditions (e.g. inflammatory bowel disease)	Fragility fracture: Prolonged use of glucocorticoids Use of other high-risk medications (aromatase inhibitors, androgen deprivation therapy, anticonvulsants) Hypogonadism or premature menopause Malabsorption syndrome Primary hyperparathyroidism Other disorders strongly associated with rapid bone loss and/or fracture	Prevention - Hi Alendronate Risedronate Denosumab Teriparatide Romosozumab Prevention - No Alendronate Risedronate Denosumab Teriparatide Romosozumab Prevention - Ve Alendronate Risedronate Risedronate	0.61 RR (0.42-0.90) 0.73 RR (0.58-0.92) 0.56 RR (0.35-0.90) 0.64 RR (0.25-1.68) 0.44 RR (0.24-0.79) 0.44 RR (0.24-0.79) 0.84 RR (0.74-0.94) 0.78 RR (0.68-0.89) 0.80 RR (0.67-0.96) 0.62 RR (0.47-0.80) 0.67 RR (0.53-0.86)

Table 32. Osteoporosis Risk Stratification

Low-Risk 10 yr fracture risk <10%	Unlikely to benefit from pharmacotherapy; encourage lifestyle changes Reassess risk in 5 yr
Medium-Risk 10 yr fracture risk 10-20%	Discuss patient preference for management and consider additional risk factors Factors that warrant consideration for pharmacotherapy: Additional vertebral fracture(s) identified on vertebral fracture assessment (VFA) or lateral spine x-ray Previous wrist fracture in individuals ≥65 yr or with T-score ≤-2.5 Lumbar spine T-score much lower than femoral neck T-score Rapid bone loss Men receiving androgen-deprivation therapy for prostate cancer Women receiving aromatase-inhibitor therapy for breast cancer Long-term or repeated systemic glucocorticoid use (oral or parenteral) that does not meet the conventional criteria for recent prolonged systemic glucocorticoid use Recurrent falls (defined as falling 2 or more times in the past 12 mo) Other disorders strongly associated with osteoporosis
	Repeat BMD and reassess risk every 1-3 yr initially
High-Risk 10 yr fracture risk >20%; OR Prior fragility fracture of hip or spine; OR More than one fragility fracture	Start pharmacotherapy (need to consider patient preference)

Treatment of Osteoporosis

Table 33. Treatment of Osteoporosis in Women and Men

Treatment for Both Men and V	Treatment for Both Men and Women			
Lifestyle	Diet: elemental calcium 1000-1200 mg/d; vitamin D 1000 IU/d Exercise: 3x30 min weight-bearing exercises, balance exercise, and aerobic exercise/wk Cessation of smoking, reduce caffeine intake Stop/avoid osteoporosis-inducing medications			
Drug Therapy				
Bisphosphonate: inhibitors of osteoclasts	1st line in prevention of hip, nonvertebral, and vertebral fractures (Grade A): alendronate (PO), risedronate (PO), zoledronic acid (IV)			
RANKL Inhibitors	Denosumab: 1st line in prevention of hip, nonvertebral, vertebral fractures (Grade A) *Denosumab should not be abruptly stopped/administration delayed. Increased risk of multiple vertebral fractures due to increased bone turnover on discontinuation. Used as an alternative initial treatment in postmenopausal women with osteoporosis who are at high risk for osteoporitic fractures.			
Parathyroid Hormone Analogue	Teriparatide: 18-24 mo duration, followed by long-term anti-resorptive therapy with bisphosphonate or RANKL inhibitor			
Sclerostin Inhibitors	Romosozumab: 12 mo duration			
Treatment Specific to Post-Me	enopausal Women			
SERM (selective estrogen-receptor modulator): agonistic effect on bone but antagonistic effect on uterus and breastRaloxifene: 1st line in prevention of vertebral fractures (Grade A) Advantages: prevents osteoporotic fractures (Grade A to B evidence), improves lipid profile, de breast cancer risk Disadvantages: increased risk of DVT/PE, stroke mortality, hot flashes, leg cramps				
HRT: combined estrogen + progesterone (see <u>Gynaecology</u> , GY37)	Indicated for vasomotor symptoms of menopause For most women, risks > benefits Combined estrogen/progestin prevents hip, vertebral, total fractures Increased risks of breast cancer, cardiovascular events, and DVT/PE			



(mail

Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A **Randomized Clinical Trial** JAMA 2019:322:736-45

Factors Necessary for Mineralization · Quantitatively and qualitatively normal

· Normal concentration of calcium and

osteoid formation

phosphate in ECF Adequate bioactivity of ALP Normal pH at site of calcification · Absence of inhibitors of calcification

Purpose: To investigate the effects of vitamin D supplementation on volumetric BMD and strength. Methods: 311 healthy adults (ages 55-70) without osteoporosis, with baseline concentrations of 25-hydroxyvitamin D of 30-125 nmol/L, were randomized to receive daily doses of 400 IU, 4000 IU, or 10000 IU vitamin D3 for 3 years. For participants with calcium dietary intake <1200 mg/d, supplementation was provided. Primary Outcome: Total volumetric BMD at radius and tibia. Results: Compared with the 400 IU group, radial volumetric BMD was significantly lower for the 4000 IU group (-3.9 mg HA/cm3; 95% confidence interval (CI), -6.5 to -1.3) and 10000 IU group (-7.5 mg HA/ cm3; 95% CI, -10.1 to -5.0) with mean % change of -1.2% (400 IU), -2.4% (4000 IU), and -3.5% (10000 IU). Compared with the 400 IU group, tibial volumetric BMD differences were -1.8 mg HA/cm3 (95% CI, -3.7 to 0.1) (4000 IU) and -4.1 mg HA/cm3 (95% CI, -6.0 to -2.2) (10000 IU), with mean % change values of -0.4% (400 IU), -1.0% (4000 IU), and -1.7% (10000 IU). Conclusion: In healthy adults, supplementation with daily 4000 IU or 10000 IU vitamin D for 3 years was associated with lower radial BMD compared with 400 IU. 10000 IU was associated with lower tibial BMD. There were no apparent benefits of high-dose vitamin D supplementation for bone health.








Figure 22. Physical examination test for vertebral fractures




Figure 42. Osteomalacia, osteopenia, and osteoporosis



Disorders Strongly Associated with Osteoporosis Include:

Primary hyperparathyroidism, T1DM, osteogenesis imperfecta, uncontrolled hyperthyroidism, hypogonadism or premature menopause (<45 yr), Cushing's disease, chronic malnutrition or malabsorption, chronic liver disease, COPD, and chronic inflammatory conditions (e.g. IBD)

10 Yr Fracture Risk Assessment

FRAX (WHO Fracture Risk Assessment Tool) and CAROC (Canadian Association of Radiologists and Osteoporosis Canada) have been validated in the Canadian Population FRAX and CAROC are available online from: https://www. osteoporosis.ca/health-care-professionals/clinical-toolsand-resources/



How Much Calcium Do We Need?

Age	Amount /day
4-8	1000 mg
9-18	1300 mg
19-50	1000 mg
>50	1200 mg



Calcium Content of Common Foods 1 cup milk = 300 mg ³/₄ cup yogurt = 332 mg ¹/₂ can salmon with bones = 240 mg ¹/₂ cup cooked broccoli = 33 mg 1 medium orange = 50 mg



Vitamin D Content in Food

- Milk fortified with vitamin D3 contains 100 IU per 250 mL glass
- Foods such as margarine, eggs, chicken livers, salmon, sardines, herring, mackerel, swordfish, and fish oils (halibut and cod liver oils) all contain small amounts; supplementation is necessary to obtain adequate levels as dietary intake has minimal impact
- Most multivitamins provide 400 IU of vitamin D3





Osteomalacia and Rickets

Definition

• osteopenia with disordered calcification leading to a higher proportion of osteoid (unmineralized) tissue prior to epiphyseal closure: rickets (in childhood), osteomalacia (in adulthood)

Etiology and Pathophysiology

Vitamin D Deficiency

- deficient uptake or absorption
 - nutritional deficiency
 - malabsorption: post-gastrectomy, small bowel disease (e.g. celiac sprue), pancreatic insufficiency
- defective 25-hydroxylation
 - liver disease
- anticonvulsant therapy (phenytoin, carbamazepine, phenobarbital)
- loss of vitamin D binding protein
- nephrotic syndrome
- decreased 1-α-25 hydroxylation
- hypoparathyroidism
- renal failure

Mineralization Defect

- abnormal matrix
- osteogenesis imperfecta
- enzyme deficiency
- hypophosphatasia (inadequate ALP bioactivity)
- presence of calcification inhibitors
- aluminum, high dose fluoride, anticonvulsants

Calcium Deficiency

- · deficient uptake or absorption
 - nutritional deficiency
 - malabsorption
- hypercalciuria (in combination with renal phosphate wasting)

Hypophosphatemia

- gastrointestinal: poor nutritional intake, chronic diarrhea, excessive phosphate binders
- renal phosphate wasting
 - tumour-induced osteomalacia
 - Fanconi syndrome
 - X-linked/autosomal dominant/recessive hypophosphatemic rickets

Matrix Abnormalities

- type IV osteogenesis imperfecta
- fibrogenesis imperfecta ossium
- axial osteomalacia

Table 34. Clinical Features of Rickets and Osteomalacia

Osteomalacia
Not as severe
Diffuse skeletal pain
Bone tenderness
Fractures
Gait disturbances (waddling)
Proximal muscle weakness
Hypotonia

Investigations

Table 35. Laboratory Findings in Osteomalacia and Rickets

Disorder	Serum Phosphate	Serum Calcium	Serum ALP	Other Features
Vitamin D Deficiency	Decreased	Decreased to normal	Increased	Decreased calcitriol
Hypophosphatemia	Decreased	Normal	Increased	
Proximal Renal Tubular Acidosis	Decreased	Normal	Normal	Associated with hyperchloremic metabolic acidosis
Conditions Associated with Abnormal Matrix Formation	Normal	Normal	Normal	

radiologic findings

- pseudofractures, fissures, narrow radiolucent lines thought to be healed stress fractures or the result of erosion by arterial pulsation
- loss of distinctness of vertebral body trabeculae; concavity of the vertebral bodies
- changes due to secondary hyperparathyroidism: subperiosteal resorption of the phalanges, bone cysts, resorption of the distal ends of long bones
- others: bowing of tibia, coxa profundus hip deformity
- bone biopsy: usually not necessary but considered the gold standard for diagnosis

Treatment

- · definitive treatment depends on the underlying cause
- vitamin D supplementation
- PO43- supplements if low serum PO43-, Ca2+ supplements for isolated calcium deficiency
- bicarbonate if chronic metabolic acidosis



KDIGO 2017 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Kidney Inter Suppl 2017;7(1):1-60

Recommendations for Metabolic Bone Disease (MBD) in Chronic Kidney Disease (CKD)

Screening

- In CKD patients with evidence of CKD-MBD and/or risk factors for osteoporosis, perform BMD testing to assess fracture risk if results will impact treatment decisions
- In patients with CKD-BMD, it is reasonable to perform a bone biopsy if knowledge of the type of renal osteodystrophy will impact treatment decisions

Management

- Treatment of CKD-MBD should be based on serial assessments of PO₄³⁻, Ca²⁺, and PTH levels, considered together
- Suggest lowering elevated PO₄³⁻ levels towards the normal range
- Avoid hyperglycemia in adult patients and maintain serum Ca²⁺ in age-appropriate normal range in children





Renal Osteodystrophy

Definition

- changes to mineral metabolism and bone structure secondary to CKD
- represents a mixture of four types of bone disease:
 - osteomalacia: low bone turnover combined with increased unmineralized bone (osteoid)
 - adynamic bone disease: low bone turnover due to excessive suppression of parathyroid gland
 - osteitis fibrosa cystica: increased bone turnover due to secondary hyperparathyroidism
 - mixed uremic osteodystrophy: both high and low bone turnover, characterized by marrow fibrosis and increased osteoids
- metastatic calcification secondary to hyperphosphatemia may occur

Pathophysiology

- metabolic bone disease secondary to chronic renal failure
- combination of hyperphosphatemia (inhibits 1,25(OH)₂ vitamin D synthesis) and loss of renal mass (reduced 1- α -hydroxylase)

Clinical Features

- soft tissue calcifications, necrotic skin lesions if vessels involved
- osteodystrophy, generalized bone pain, and fractures
- pruritus
- neuromuscular irritability and tetany may occur (with low serum calcium)
- radiologic features of osteitis fibrosa cystica, osteomalacia, osteosclerosis, osteoporosis

Investigations


• serum Ca²⁺ corrected for albumin, PO₄³⁻, PTH, ALP, ± imaging (x-ray, BMD), ± bone biopsy (gold standard; only done if results inform treatment)

Treatment

- prevention
- maintenance of normal serum Ca²⁺ and PO₄³⁻ by restricting PO₄³⁻ intake to 1 g once daily
- Ca²⁺ supplements; PO₄³⁻ binding agents (calcium carbonate, aluminum hydroxide)
- activated vitamin D (calcitriol) with close monitoring to avoid hypercalcemia and metastatic calcification
- bisphosphates and denosumab are not often used for treatment (can worsen the adynamic components of renal osteodystrophy); bone biopsy may indicate if there are signs of increased bone turnover amenable to bisphosphonates



Q1: Which of the following is a sign of rickets on an X ray?






SAQs

441 & 439 & 438:

- Name 2 factors mentioned in the lecture that control bone metabolism you think are the most important ones? And explain why for each point.?
 Page 4
- Sketch a tibia (bone) demonstrating two rickets radiographic findings labeled in the sketch.
 Page 14



Done by Abdulrahman Alroqi

Special Thanks

Khalid Alqahtani Abdullah Alomran

وفّقكم الله



This work was originally done by team 438 & 439

